AQWA vs CNM

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where AQWA's RSI Indicator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.

The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on AQWA as a result. In 71 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for AQWA just turned positive on October 02, 2026. Looking at past instances where AQWA's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.

Following a +0.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where AQWA advanced for three days, in 266 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

AQWA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 50-day moving average for AQWA moved below the 200-day moving average on September 10, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQWA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for AQWA entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CNM as a result. In 53 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

The Moving Average Convergence Divergence Histogram (MACD) for CNM turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CNM's RSI Oscillator exited the oversold zone, 16 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 55 cases where CNM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

Following a +1.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNM advanced for three days, in 251 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

CNM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.849) is normal, around the industry mean (7.841). P/E Ratio (17.444) is within average values for comparable stocks, (134.538). Projected Growth (PEG Ratio) (1.451) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (1.090) is also within normal values, averaging (3.013).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. CNM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 68 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.